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ABSTRACT
Viral diseases are a major cause of morbidity and mortality after hemopoietic stem cell transplantation. Because
viral complications in these patients are clearly associated with the lack of recovery of virus-specific cellular
immune responses, reconstitution of the host with in vitro expanded cytotoxic T lymphocytes is a potential
approach to prevent and treat these diseases. Initial clinical studies of cytomegalovirus and Epstein-Barr virus
in human stem cell transplant patients have shown that adoptively transferred donor-derived virus-specific T
cells may restore protective immunity and control established infections. Preclinical studies are evaluating this
approach for other viruses while strategies for generating T cells specific for multiple viruses to provide
broader protection are being evaluated in clinical trials. The use of genetically modified T cells or the use of
newer suicide genes may result in improved safety and efficacy.
© 2004 American Society for Blood and Marrow Transplantation
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hNTRODUCTION
One of the major causes of morbidity and mortal-
ty in patients who receive allogeneic hematopoietic
tem cell transplants (HSCT) is viral infection during
he period of immune deﬁciency that follows the pro-
edure. Recovery of antiviral immunity is dependent
n engraftment and expansion of the donor immune
ystem, which occurs by a combination of peripheral
ature T-cell expansion and thymopoiesis [1]. The
isk of viral infection relates to a number of factors,
ncluding the type of transplant, processing of the
raft, and posttransplantation immunosuppression. In
any cases, viral infection after bone marrow trans-
lantation (BMT) results from reactivation of a latent
irus, and herpes viruses such as cytomegalovirus
CMV), Epstein-Barr virus (EBV), and herpes simplex
nd herpes zoster are common viral pathogens that
ause disease after transplantation. In addition, respi-
atory viruses such as adenovirus, inﬂuenza, and re-
piratory syncytial virus (RSV) also pose a serious
roblem in posttransplantation patients, who usually
cquire the viruses from contact with infected individ- s
B&MTals. Although pharmacologic agents are available for
he prophylaxis and treatment of some of these vi-
uses, they are expensive, have signiﬁcant toxicities,
nd can delay viral-speciﬁc immune reconstitution.
Because viral complications in these patients are
learly associated with the lack of recovery of virus-
peciﬁc cellular immune responses, immunotherapeu-
ic strategies to restore viral-speciﬁc immunity are an
ttractive alternative. The most important component
f the cellular immune response that controls most
iral infections is CD8 cytotoxic T lymphocytes
CTLs) that recognize peptides derived from viral
roteins complexed to major histocompatibility com-
lex (MHC) class I molecules. CD4 virus-speciﬁc T
ells also play an essential role in providing help to
D8 cells and producing long-term immunity. Over
he past decade, interest in immunotherapy ap-
roaches has been stimulated by studies showing that
onor T cells have efﬁcacy in treating viral infections
2,3]. Because unmanipulated T-cell populations also
ontain alloreactive T cells, a number of investigators
ave explored whether patients can be protected from
uch viruses by adoptive transfer of virus-speciﬁc
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1TLs. Clinical trials have been undertaken that target
MV and EBV, and approaches that target other
iruses are under development.
There are several requirements for generating vi-
us antigen–speciﬁc CTLs ex vivo. First, virally in-
ected cells must express unique proteins capable of
roviding epitopes for speciﬁc immune responses. It is
rucial to know which antigens are expressed by virally
nfected cells and which antigens are most important
or viral persistence and, thus, the best targets for
mmunotherapy strategies. The viral antigens ex-
ressed at different stages of viral infection have been
ell characterized for some viruses, such as CMV and
BV, but are less well deﬁned for other viruses that
ause morbidity, such as adenovirus. Over the past few
ears, antigen identiﬁcation has been simpliﬁed by the
vailability of molecular techniques, and bioinformat-
cs tools have enabled peptide mapping of speciﬁc
pitopes recognized by CD4 and CD8 T cells.
Another requirement is an effective antigen-pre-
enting cell (APC) that must express MHC antigens,
resent relevant virus-derived peptides frequently
nough and for sufﬁcient duration to engage re-
ponder T cells, and express co-stimulatory molecules
uch as CD28 to induce T-cell activation. The choice
f APC to study also depends on the type of antigen to
e used and the proposed method of delivery. Table 1
hows, by using CMV as a model, that there is a wide
ange of possible choices for both APC and source of
ntigen. Some approaches use whole virions, whereas
thers use speciﬁc viral genes or peptides, and target
ells include ﬁbroblasts, dendritic cells (DCs), and B
ells. One of the limitations of adoptive immunother-
py is the lack of a convenient source of APCs neces-
ary to generate antigen-speciﬁc CTLs. Most current
PCs used in clinical trials require prolonged in vivo
ulture or manipulation before the initiation of CTL
eneration. A number of approaches being explored in
reclinical studies simplify this process. These include
rtiﬁcial APCs that express ligands for the T-cell re-
eptor (TCR) and the CD28 and 4-1BB co-stimula-
ory surface molecules [4]; mouse ﬁbroblasts retrovi-
ally transduced with a single HLA/peptide complex
able 1. Different Sources of Antigens and Antigen-Presenting Cells in
Antigen
irions Skin
etroviral vector encoding pp65 B ly
denoviral vector encoding pp65 Den
denoviral vector encoding pp65 Den
MV antigen derived from CMV-infected lung fibroblasts Den
MV lysate and antigen Per
LA-A*0201-restricted CMV peptide pp65(495-503) Den
LA-A*0201-restricted CMV peptide pp65(495-503) Denlong with the human accessory molecules B7.1, in- E
44ercellular adhesion molecule-1, and leukocyte func-
ion-associated antigen [LFA]-3 [5]; and beads cou-
led to soluble HLA-immunoglobulin fusion protein
nd CD28-speciﬁc antibody [6].
It is also preferable when ex vivo CTL generation
s undertaken that the donor be seropositive for the
irus, because it is easier to reactivate a secondary
mmune response ex vivo than to generate a primary
ne. This is not a major limitation for approaches
argeting EBV, because transfer of EBV-infected B
ells in the infused product is the major cause of EBV
ymphoproliferation. Recipients of seronegative do-
ors are therefore at low risk of developing EBV
ymphoma. However, CMV reactivation usually oc-
urs from endogenous virus, and seropositive recipi-
nts with seronegative donors are a high-risk group.
n preclinical studies, early selection of low-frequency
irus-speciﬁc cells may enable CTL generation from
eronegative donors [7].
MMUNOTHERAPY TARGETING SPECIFIC VIRUSES
pstein-Barr Virus
EBV is an enveloped herpesvirus with a 172-kilo-
ase double-stranded DNA genome [8]. In the immu-
ocompetent host, EBV infection results in a mild
elf-limiting illness [9]. Like other herpes viruses,
BV persists by a combination of latent infection in B
ells and productive replication in B cells or mucosal
pithelium. There are 3 types of EBV latency, which
re deﬁned by the number and type of latent proteins
xpressed on the host’s B cells. In type 1 latency, only
he EBNA1 gene is expressed, whereas in type 2 la-
ency, EBNA1, LMP1, and LMP2 are expressed. B
ells expressing type 3 latency express of all the 9
atency-associated EBV proteins, including the immu-
odominant EBNA3 viral antigens, and the presence
f cell adhesion and co-stimulatory molecules that
ake these B cells highly immunogenic and, in the
mmunocompetent host, susceptible to immune-me-
iated killing by EBV-speciﬁc CTLs [10]. Type 3
atency is also demonstrated in vitro in immortalized
ical and Clinical Studies Generating CMV-Speciﬁc CTLs
Antigen-Presenting Cell Reference
last Walter et al. [51]
lastoid cell line Sun et al. [36]
cells Keever-Taylor et al. [56]
Hamel et al. [72]
cells and B lymphoblastoid cell line Sifi et al. [58]
cells Peggs et al. [54]
blood mononuclear cells Einsele et al. [55]
cells and B lymphoblastoid cell line Szmania et al. [92]
cells Foster et al. [93]Preclin
fibrob
mphob
dritic
dritic
dritic
ipheral
dritic
driticBV-transformed lymphoblastoid B-cell lines (LCL).
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Adoptive Immunotherapy for Posttransplantation Viral Infections
BHowever, after transplantation, when CTL num-
ers or activity are suppressed, EBV-infected B cells
xpressing a type 3 latency may proliferate in an un-
ontrolled manner. This is also associated with an
ccumulation of EBV-infected B cells in the body,
ith increased levels of EBV DNA detected in the
eripheral blood by polymerase chain reaction (PCR)
11-14], and, in many cases, with the development of
ymphoma.
Incidence. The reported incidence of lymphopro-
iferative disease (LPD) after HSCT ranges from
1% to 25% of transplant recipients [15]. The inci-
ence is highest in the ﬁrst 6 months after transplan-
ation (120 cases per 10000 patients per year) [15]. In
multivariate analysis, the risk of LPD at12 months
fter HSCT was shown to be strongly associated with
atients who received HSCT from HLA-mismatched
amily donors or unrelated donors [15]. Moreover,
isk was increased depending on the posttransplanta-
ion immunosuppression regimen used or whether the
arrow was depleted of T cells to prevent graft-
ersus-host disease [16-20]. However, if both T and B
ells were depleted simultaneously, the incidence was
uch lower [21].
Treatment with Pharmacologic Agents and Monoclo-
al Antibodies. A variety of therapeutic approaches to
PD after HSCT have been explored. Although with-
rawal of immunosuppression is often effective in sol-
d-organ recipients, this strategy is not usually effec-
ive in HSCT recipients because the developing
onor-derived immune system cannot provide sufﬁ-
ient immune recovery to eradicate EBV-infected B
ells. Chemotherapy regimens such as cyclophospha-
ide, hydroxydaunomycin, vincristine, and pred-
isone have been used to treat LPD after HSCT, but
ortality is high secondary to signiﬁcant toxicity [22].
ther drugs, including interferon-2b and intrave-
ous immune globulin, and antiviral agents such as
cyclovir have also been used to treat LPD in this
etting. However, a limitation with the use of antiviral
gents is that EBV-transformed cells are latently in-
ected, and these drugs block only active herpes virus
eplication and do not affect the growth of cells that
re already transformed. The use of monoclonal anti–
-cell antibodies such as anti-CD20 has also been
nvestigated for the treatment of this disease. Al-
hough follow-up is relatively short and the number of
atients in each series is relatively small, the overall
esponse rates with anti-CD20 ranged from 69% to
00%, and this agent therefore represents a promising
trategy for LPD after HSCT [23,24]. However, there
re potential hazards of CD20 therapy, because the
rofound B-cell depletion may further exacerbate im-
unodeﬁciency in transplant recipients and may re-
ult in selection of a CD20 population of proliferat-
ng B cells [25].T-Cell Therapy for EBV. Immunotherapeutic strat- m
B&MTgies aimed at reconstituting T-cell responses to EBV
ave now been used for more than 10 years and have
mproved the outcome of EBV/LPD after transplan-
ation. In addition, techniques to detect the disease
arly have been developed that allow preemptive ther-
py [11,26-28]. In the ﬁrst reported study from Sloan-
ettering, unselected populations of donor lympho-
ytes were administered to HSCT recipients with
stablished EBV/LPD [2]. The rationale for this strat-
gy was that most EBV-seropositive individuals have a
igh frequency of EBV-speciﬁc precursors, so transfer
f unmanipulated donor lymphocyte populations
hould be able to restore the immune response to
BV. In the Sloan-Kettering experience, the overall
esponse rate was high: 20 of 22 patients attained
omplete remissions [17]. Other centers have seen
ower response rates to donor leukocyte infusions [12];
his may reﬂect different patient populations or a
etter outcome with early diagnosis and treatment.
oreover, such therapy is limited by potentially fatal
omplications that arise from alloreactive T cells also
resent in the lymphocyte infusion [12,29].
One approach to overcome the problem of allo-
eactivity is to use antigen-speciﬁc T-cell lines, and
esults of clinical trials that have used this strategy to
arget EBV are summarized in Table 2. Although
ther treatment modalities such as rituximab are now
vailable for the therapy of EBV lymphomas, this was
n excellent model to evaluate antigen-speciﬁc CTLs
ecause in most EBV-LPD cases that occur in hema-
opoietic stem cell recipients, the transformed cells are
f donor origin and express all latent cycle virus-
ssociated antigens, providing excellent targets for vi-
us-speciﬁc T cells. EBV-transformed LCLs that ex-
ress the same array of viral proteins can be readily
repared from any donor and provide a source of
PCs that endogenously express the appropriate an-
igens for presentation of HLA class I–restricted
pitopes. Our group generated EBV-speciﬁc T-cell
ines from donor lymphocytes and used them as pro-
hylaxis and treatment for EBV-induced lymphoma in
atients after HSCT [30-32]. APCs for CTL reacti-
ation were generated by infecting donor peripheral
lood mononuclear cells (PBMC) with a laboratory
train of EBV to generate a donor LCL line. These
CLs were irradiated and then used as APCs to stim-
late and expand EBV-speciﬁc CTLs from the donor
ymphocyte population. The resultant EBV-speciﬁc
TLs are polyclonal and contain both CD4 and
D8 EBV-speciﬁc T cells. This is considered ad-
antageous because the presence of antigen-speciﬁc
D4-helper T cells is important for in vivo survival of
ytotoxic CD8 T-cell populations. Since 1993, 58
atients who received a T cell–depleted HSCT were
iven EBV CTLs prophylactically. The ﬁrst 26 pa-
ients received CTLs that which were genetically
odiﬁed with a retroviral vector that encoded the
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1eomycin-resistance gene. None of these patients who
eceived EBV CTLs as prophylaxis developed LPD,
ompared with 11.5% in a comparable group that did
ot receive CTLs [16]. Nine patients had high EBV
NA levels in peripheral blood before CTL infusion,
hich was predictive of the imminent onset of EBV/
PD, and had a rapid decrease in EBV DNA levels
hat correlated with an increase in EBV-speciﬁc CTL
recursor frequency. By using conventional PCR and
eal-time PCR, the marker gene was identiﬁed in
he peripheral blood up to 78 months after CTL
Table 2).
Six patients have also been treated for established
BV lymphoma. The EBV-speciﬁc CTL therapy in-
uced remissions in 5 patients, although in 1 case
igniﬁcant inﬂammation occurred at sites of disease
fter CTL administration [32]. The patient whose
reatment failed was found to have an escape mutant
n her tumor cells. Therefore, although the donor
BV CTL line recognized 2 immunodominant HLA
11–restricted epitopes in EBNA3B, the patient’s tu-
or cells had a mutation in the EBNA3B epitope,
hereby rendering the tumor resistant to the donor
TL [33]. Although polyclonal CTL lines were used,
uch lines may have target antigen restriction after
nly 1 week of culture [34], and a restricted pattern of
CR use on spectratyping has been observed [35] that
s likely due to the immunodominance of particular
BV-derived peptides presented in the context of dif-
erent HLA types [10]. Therefore, the risk of tumor
scape mutants remains a concern, as it does with the
se of monoclonal antibody therapies. In addition, the
able 2. Published Reports on Use of EBV-Cytotoxic T Cells as Prophy
Study
No. Patients
(Patient
Age Range) Type of Transplant
ooney et al.
[32]
39 (9 mo to 20 y) T cell–depleted HSCT
(mismatch related
donor or matched
unrelated donor)
ooney et al.
[32] and
Gottschalk
et al. [33]
3 (12-17 y) T cell–depleted HSCT
ustafsson
et al. [13]
6 (1-39 y) T cell–depleted HSCT or
unmanipulated HSCT
with ATG/OKT3
conditioning
(mismatched or
matched unrelated
donor or matched
related donor)
TLD indicates posttransplantation lymphoproliferative disorder.nfusion of CTL to patients with incipient or estab- c
46ished disease warrants caution because of the risk of
n inﬂammatory response at disease sites. However,
doptively transferred EBV CTLs do persist long-
erm and can prevent and effectively treat EBV-driven
PD.
A study from Sweden has conﬁrmed the efﬁcacy of
BV-speciﬁc CTLs in reducing the viral load in pa-
ients with high EBV DNA levels after HSCT [13].
owever, 1 of 6 patients who received EBV-speciﬁc
TLs subsequently developed overt EBV/LPD and
ied of progressive disease. In vitro testing of the
onor CTL line of this patient showed that it lacked a
trong EBV-speciﬁc component, which may explain
his failure of CTL therapy.
An additional limitation of CTL therapy is that
ecause posttransplantation LPD requires immediate
reatment, CTLs must be available at diagnosis. The
eneration of EBV-speciﬁc CTLs requires 2 to 3
onths, although use of EBV antigen–loaded DCs as
PCs can reduce this time. Another strategy recently
escribed by Koehne et al. [34] is to select virus-
peciﬁc cells early in culture by their susceptibility to
ransduction with a retroviral vector. Another concern
s that if this strategy is used prophylactically, recipi-
nts are protected from only 1 of the many viruses that
ay cause morbidity and mortality during the period
f immunosuppression after transplantation. Several
roups have investigated approaches for modifying
he LCLs used as APCs to generate multispeciﬁc
TLs. Transduction of LCLs with a retroviral vector
ncoding pp65 has allowed generation of CTLs spe-
Treatment for PTLD after BMT
logic Evidence
of PTLD
Cytotoxic T-Cell
(CTL)
Lines and Dose Results
rophylaxis
y
Allogeneic (donor-
derived) EBV CTL:
minimum dose of
4  107/m2 and
maximum dose of
12  107/m2
No patients developed
PTLD compared with
11.5% of controls: no
toxicity
ymphoblastic
phoma
Allogeneic (donor-
derived) EBV CTL
2-4  107/m2
2 compete remissions,
1 died (no response
to CTL secondary to
tumor mutation
resistant to CTL)
reatment
d on
eased EBV
levels
Allogeneic (donor-
derived) EBV CTL
4  107/m2
5 patients had decreased
EBV DNA levels. 1
patient subsequently
died of PTLD (CTL
showed poor
specificity for EBV
targets on cytotoxicity
assay)laxis or
Patho
No—p
stud
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Adoptive Immunotherapy for Posttransplantation Viral Infections
Bf LCLs with adenovirus results in the generation of
TLs speciﬁc for both adenovirus and EBV [37].
ytomegalovirus
CMV is a member of the beta herpes viruses; its
athology is associated with its lytic cycle. CMV is
atent in approximately 70% of individuals and repli-
ates slowly in a wide range of cells, including epithe-
ial cells and ﬁbroblasts, and monocytes are thought to
e the source of latent infection. Although rarely as-
ociated with signiﬁcant illness in immunocompetent
ndividuals, CMV causes signiﬁcant morbidity and
ortality in the immunocompromised host [38].
Incidence. In the absence of preventive measures,
he incidence of CMV infection is 60% to 70% for
eropositive allograft recipients in the ﬁrst 100 days
fter transplantation. CMV causes interstitial pneu-
onitis, gastroenteritis, and a systemic wasting syn-
rome, and CMV seropositivity is an independent risk
actor for adverse outcomes [39]. Further, with the
ncreasing use of so-called submyeloablative or re-
uced-intensity, highly immunosuppressive condi-
ioning regimens, higher rates of CMV infections and
eactivation have been observed that are due to pro-
onged immune suppression [40,41]. In addition, the
nset of CMV disease/reactivation is observed at later
ime points with these regimens (130 days versus 52
ays after transplantation in recipients of fully ablative
onditioning regimens), and late CMV disease has
ecome a major problem [42]. Finally, CMV viremia
n posttransplantation patients can result in prolonga-
ion of immunodeﬁciency and delay CMV-speciﬁc
mmune recovery and expansion even further.
Prevention and Treatment with Pharmacologic
gents. The most frequently used drugs for prophy-
actic or preemptive antiviral therapy are ganciclovir
nd foscarnet. These drugs, in combination with in-
ravenous immune globulin, have been successful in
educing the mortality associated with CMV disease
nd in preventing early CMV disease [43]. However,
rophylaxis or preemptive treatment with ganciclovir
r foscarnet has signiﬁcant side effects (neutropenia
nd nephrotoxicity, respectively) and is expensive. Ci-
ofovir has also been used as primary preemptive
herapy after transplantation but is associated with
enal toxicity, as well as a failure rate of up to 34%
44,45]. Patients receiving ganciclovir are more likely
o develop myelosuppression that results in neutrope-
ia and thrombocytopenia (frequency 41%-58%),
hich necessitates the administration of granulocyte
olony-stimulating factor [46,47]. In addition, pro-
hylactic or preemptive therapy delays recovery of
MV-speciﬁc CD4 and CD8 lymphocytes, and this
esults in an increased risk of developing persistent or
ate CMV disease (100 days after allogeneic BMT)
40]. a
B&MTT-Cell Therapy for CMV. Initially, studies per-
ormed in the murine CMV model showed that trans-
er of CD8 murine CMV–speciﬁc CTLs protected
he mice from fatal CMV infection. CMV-speciﬁc
-cell responses after HSCT have been studied by
everal groups. In a recent study with tetramers, Cwy-
arski et al. [48] studied 24 recipients of allogeneic
tem cell transplants (SCT) and found that recovery of
MV-speciﬁc CTLs to levels 10  106/L was asso-
iated with protection from CMV disease. Further,
lthough CMV-speciﬁc CTLs recovered approxi-
ately 50 days after transplantation in patients after
atched related donor BMT, they were absent during
he ﬁrst 100 days in matched unrelated donor trans-
lant recipients. Reconstitution of CD4 immunity
howed similar kinetics [49].
Another group assessed not only the number, but
lso the function, of CMV-speciﬁc CTLs after HSCT
y using tetramer and intracellular cytokine staining.
hey found that individuals who experienced CMV
ntigenemia had lower fractions of functional (tumor
ecrosis factor-–secreting) CMV-speciﬁc CTLs
resent than subjects who did not (25% versus 65%;
 .015). Furthermore, individuals at high risk for
MV reactivation, such as patients with acute graft-
ersus-host disease, had signiﬁcantly lower fractions
f cytokine-producing CMV-speciﬁc T cells. These
ata suggest that the inability to control CMV reac-
ivation after allogeneic SCT is due not only to low
ntigen-speciﬁc T-cell numbers, but also to impair-
ent of the T-cell function in vivo [50]. Such studies
elp to conﬁrm the rationale behind adoptively trans-
erring donor-derived CMV-speciﬁc CTLs to at-risk
atients after HSCT.
The immune response to CMV is well under-
tood, the CMV matrix protein pp65 has been iden-
iﬁed as bearing immunodominant epitopes against a
ange of HLA backgrounds, and CD8 clones speciﬁc
or pp65 protect against CMV disease in humans. In a
roof-of-principle study, CMV prophylaxis with
doptively transferred, donor-derived CMV-speciﬁc
TLs was ﬁrst explored by Walter et al. [51]. This
roup expanded and infused CMV-speciﬁc CD8
lones in a dose-escalation study in allogeneic
atched sibling SCT recipients. There were no ad-
erse events, and functional CMV-speciﬁc CD8 T-
ell responses were detected in all patients after infu-
ion [51]. However, the expansion of T-cell clones to
chieve adequate dose levels is extremely time con-
uming. Also, the authors reported that the magnitude
f their anti-CMV responses declined in those who
acked detectable CD4 CMV-speciﬁc T-cell re-
ponses, which is a concern when CD8 T-cell clones
re used as opposed to polyclonal (CD4 and CD8)
TL lines. Further, studies have shown that CD4 T
ells are required for long-term persistence of these
doptively transferred CD8 clones [52]. Nevertheless,
147
n
d
t
C
c
c
E
C
ﬁ
d
B
A
r
a
w
i
s
g
u
a
ﬁ
t
a
e
t
P
i
d
a
w
r
m
p
e
g
t
G
l
p
t
g
C
C
t
C
r
a
a
P
b
s
w
d
m
s
c
T
W
E
P
C
M
C. M. Bollard et al.
1o patient who received these infusions went on to
evelop CMV disease, which demonstrates the impor-
ance of functional CD8 T cells in the control of
MV reactivation after SCT [51].
One problem with the ex vivo generation of poly-
lonal CMV-speciﬁc CTLs is that unlike EBV-spe-
iﬁc CTLs, which can be generated with autologous
BV-transformed LCLs as APCs, CTLs speciﬁc for
MV must be activated by exposure to CMV-infected
broblasts or DCs transduced with 1 of the immuno-
ominant CMV antigens, such as pp65 or pp150.
ecause of the requirement for donor ﬁbroblasts as
PCs in the study by Walter at al. [51], patients
eceiving transplants from unrelated donors, who are
t increased risk of developing CMV reactivation,
ere excluded from this approach.
Table 3 provides an outline of the published clin-
cal trials that have used adoptively transferred CMV-
peciﬁc CTLs. In one approach, Peggs et al. [53,54]
enerated CMV-speciﬁc CD4 and CD8 T cells by
sing 2 or 3 stimulations with DCs pulsed with CMV
ntigen derived from a CMV-infected human lung
broblast cell line. The use of the entire CMV antigen
herefore enables a broad CTL response to be gener-
ted, as opposed to a solely pp65-speciﬁc response, for
xample. Patients were monitored for CMV reactiva-
ion, and T-cell lines were infused at the time of ﬁrst
CR reactivity. There were no infusion-related toxic-
ties, and none of the 13 patients treated with a single
5
able 3. Published Reports on the Use of CMV-Cytotoxic T Cells as Pr
Study
No. Patients
(Patient
Age Range) Type of Transplant
alter et al.
[51]
14 (16-53 y) MRD BMT (unmanipulated
graft); CSA or FK506
prophylaxis
insele et al.
[55]
8 (7 evaluable)
(30-56 y)
MRD, MMRD, and MUD
(4 patients received
CD34-selected stem cells
6 had ATG; 7 had CSA
eggs et al. [53],
Peggs and
Mackinan [94]
13 (age not
specified)
Allogeneic MRD or MUD
obbold et al.
[60]
7 (age not
specified)
Allogeneic SCT
(unmanipulated graft)
RD indicates matched related donor; CSA, cyclosporin A; MM
matched unrelated donor.ose of 10 /kg CMV CTLs developed CMV disease, t
48lthough 7 patients did develop CMV reactivation and
ere successfully treated with ganciclovir [53]. These
esults are encouraging, but potential problems re-
ain, including the use of an allogeneic cell line to
roduce the CMV antigen, which could theoretically
licit an allospeciﬁc CTL response. In this study,
rade I GVHD of the skin developed in only 3 pa-
ients, but these patients had early withdrawal of their
VHD prophylaxis, so it is unclear whether the cel-
ular therapy precipitated the GVHD or not. Another
roblem with this approach and all other approaches
hat rely on DC stimulations is the logistic problem of
enerating adequate numbers of DCs to expand the
TLs.
With the experience obtained with CMV-speciﬁc
TLs prophylactically, Einsele et al. [55] investigated
he therapeutic application of adoptively transferring
MV-speciﬁc CTLs to patients with persisting or
ecurring CMV infection despite the prolonged use of
ntiviral medications. All the patients lacked measur-
ble CMV-speciﬁc T-cell responses. Donor-derived
BMCs were pulsed with CMV lysate and expanded
y using autologous irradiated feeder cells, CMV ly-
ate, and interleukin-2. This group treated 8 patients
ho had received a CD34-selected SCT from a family
onor. After transfer of 1  107 T cells per square
eter, there were no adverse events, and despite ces-
ation of antiviral medications, the CMV load de-
reased signiﬁcantly in 7 evaluable patients. In 5 pa-
 
is or Treatment for CMV Infection after BMT
inical Evidence
CMV Disease
Cytotoxic
T-Cell (CTL)
Lines and Dose Results
CD8 CMV-
specific CTL
clones
No toxicity; functional
immunity detected in all;
no patients developed
CMV viremia or disease3.3  107/m2 to
1  109/m2
V colitis
n  1), CMV,
nterstitial
neumonitis
n  1)
Polyclonal CD4
> CD8 CMV-
specific CTL
1  107/m2
No toxicity; CMV DNA
undetectable in 6/7
patients after CTL;
Increased functional
immunity in 5 patients; 2
non responders had
increased immune
suppression
—administered
hen CMV
NA was
etected
Polyclonal CD8
and CD4 lines
No toxicity, massive
expansion, CMV-specific
immune response
HLA peptide-
selected CD8
T cells
1  105 to 2  106
Functional immunity
detected in all; 1 patient
with drug resistant CMV
antigens became CMV
negative
ismatched related donor; ATG, antithymocyte globulin; MUD,ophylax
Cl
of
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);
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Adoptive Immunotherapy for Posttransplantation Viral Infections
Bpeciﬁc T cells was seen, and the antiviral effect was
ustained [55]. Two patients, however, had a reactiva-
ion of their CMV, but this was associated with an
ntensiﬁcation of their immune suppression around
he time of the T-cell infusion. The advantage with
his approach is that it avoids the use of DCs and relies
nstead on the monocytes infected with the CMV
ysate for antigen presentation. However, the CMV
ysate contains infectious CMV, and this decreases the
ttractiveness of this approach in view of the risk of
ransferring live CMV to immunocompromised pa-
ients.
Another strategy to generate donor-derived
MV-speciﬁc CTLs is the genetic modiﬁcation of
Cs that direct the CTL response to virally trans-
uced genes [56,57]. This approach allows expression
f whole proteins, which leads to the presentation of
ultiple undeﬁned antigen epitopes. We found that
lthough DCs expressing pp65 from an adenoviral
ector effectively activated and expanded MHC class
– and II–restricted CMV-speciﬁc CTLs from
BMCs, the limiting monocyte-derived DC numbers
indered the expansion of the CTLs to the numbers
ecessary for adoptive transfer protocols [58]. We
herefore assessed the feasibility of using 1 or 2 stim-
lations with DCs transduced with the recombinant
denoviral vector expressing pp65 (Ad5f35pp65) fol-
owed by stimulations with LCLs transduced with the
ame Ad5f35pp65. Using this method, we were able to
ffectively expand pp65-speciﬁc CTL lines without
ompetition from EBV-speciﬁc CTLs; this suggests
hat the critical point for expansion of these poly-
lonal, antigen-speciﬁc CTL lines was the unlimited
ource of APCs that could present antigens in the
ppropriate MHC context. On the basis of these re-
ults, a clinical trial has been initiated.
Lucas et al. [59] have published a phase I/II clin-
cal protocol for the generation and infusion of CMV-
peciﬁc CTLs that also capitalizes on the LCLs as an
ffective and abundant source of APC. In their pro-
ocol, the CTL line is initiated by culturing donor-
erived PBMCs with irradiated donor-derived LCLs
ransduced with a retrovirus (murine stem cell virus)
hat expresses pp65. Two further stimulations with
he transduced LCLs are performed before the CMV-
nd EBV-speciﬁc cytolytic activity of the line are
ssessed. Clinical data are not yet available from this
tudy.
A ﬁnal approach that avoids the use of an APC is
o select donor-derived CMV-speciﬁc CD8 T cells
fter staining with HLA/peptide tetramers. In a study
valuating this approach, 4 patients received between
 105 and 2  106 CMV tetramer-staining CTLs.
MV-speciﬁc CTLs were detectable at increasing
evels in the peripheral blood after infusion, and all
atients became CMV negative, including 1 patient
ith drug-resistant disease [60]. This approach is v
B&MTherefore promising but, again, is limited to a small
umber of donors who have a known HLA-restricted
MV peptide epitope. Other limitations are the risk
f escape mutants because of the restricted virus-
peciﬁc response transferred and the lack of a source
f clinical-grade tetramer reagents.
denovirus
Adenoviruses are nonenveloped lytic DNA viruses
apable of infecting most animal species. Pathogenic-
ty varies according to group and type, and although
cute infection is sometimes severe, it is rarely fatal in
therwise healthy adults. Initial infection ultimately
esults in cell destruction. However, adenoviruses do
ersist and can be detected months after primary ex-
osure. Humans are susceptible to infection with 51
erotypes of adenovirus that form 6 distinct groups (A
o F) [61]. Adenoviruses generally infect mucosal ep-
thelium, but the serotypes differ in their tissue spec-
ﬁcity and virulence [62]. After viral infection, tran-
cription is temporally regulated, beginning with
mmediate early genes encoded in the E1A region,
ollowed by the delayed early units—E1B, E2, E3, E4,
nd L1. Approximately a third of the viral genome is
evoted to counteracting the antiviral immune re-
ponse. These viral immune-evasion strategies ensure
rolonged survival of infected cells and facilitate virus
ransmission [63]. The early expression of immune-
vasion genes is likely to inhibit immunity to most of
he early and late antigens. For this reason, immuno-
herapeutic strategies need to target immunodomi-
ant virion proteins that access the endosomal/lyso-
omal pathway and cytosol by receptor-mediated
ndocytosis and endosomolysis and that are then pre-
ented to the immune response before immune-eva-
ion functions are expressed.
Incidence. The pathogenicity of adenoviruses varies
ccording to group and type, and, although acute
nfection is sometimes severe, it is rarely fatal in oth-
rwise healthy adults. Thus, in healthy individuals, the
ntiviral immune response of the host controls the
xtent of virus replication and spread. However, ad-
noviruses are one of a group of opportunistic patho-
ens of immunosuppressed patients, in whom severe,
rolonged, and even fatal infections are common. The
requency of severe adenovirus disease is increasing in
ssociation with growing numbers of immunocom-
romised individuals, and fatality rates as high as 50%
o 80% have been reported [64-66]. Lion et al. [65]
rospectively studied the incidence of adenovirus in-
ection and disease in 132 consecutive pediatric SCT
atients and found that 27% tested positive for ade-
ovirus by PCR from multiple sites, including periph-
ral blood, stool, urine, and throat. It is important to
ote that 82% of patients who had detectable adeno-
irus in peripheral blood died from infectious compli-
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1ations. This incidence increases in high-risk recipi-
nts who receive T cell–depleted stem cells from
nrelated or HLA-mismatched related donors. Ap-
roximately 70% of those with detectable adenovirus
n the serum develop fatal adenoviral disease associ-
ted with hemorrhagic cystitis, pneumonia, nephritis,
epatitis, colitis, and pancreatitis [67,68]. SCT recip-
ents succumb to a range of adenovirus serotypes;
ost commonly, types 7, 11, 34, and 35 from group B
nd types 2 and 5 from group C have been detected.
Pharmacologic Treatment. Treatment options for
denoviral disease are limited, with anecdotal reports
f success with antiviral medications. The most fre-
uently used drug for the treatment of adenoviral
nfections is cidofovir [69,70]. Although there are an-
cdotal reports of responses to cidofovir, there are no
pproved antiviral agents that have proven efﬁcacy for
he treatment of severe adenoviral disease, nor are
here any prospective, randomized, controlled trials of
otentially useful antiadenoviral therapies [67]. As
een with CMV infection, the increasing use of sub-
yeloablative, highly T cell–immunosuppressive con-
itioning regimens has resulted in higher rates of
denovirus infections/reactivations being observed.
he onset of adenovirus disease/reactivation has re-
ently been reported to occur at a median of 18 days
fter transplantation (range, day 7 to day 100 or
ore) [65].
T-Cell Therapy for Adenovirus. Because viral com-
lications in these patients are clearly associated with
he lack of recovery of virus-speciﬁc cellular immune
esponses, reconstitution of the host with in vitro
xpanded CTLs is a potential approach to prevent and
reat these diseases. However, no adenovirus-speciﬁc
D8 T epitopes have been described, so it is impos-
ible to use a peptide-pulsed DC approach. In addi-
ion, as discussed previously, CMV-speciﬁc CTLs
ave been activated by DCs pulsed with CMV lysate,
nd a similar approach could be used for adenoviruses.
owever, this use of infectious adenovirus decreases
he attractiveness of this approach (as it does for
MV) in view of the risk of transferring live adeno-
iruses to immunocompromised patients.
A promising strategy for the generation of donor-
erived adenovirus-speciﬁc CTLs is to use an APC
onocyte–derived DC transduced with a replication-
efective adenoviral vector that directs the CTL re-
ponse to viral capsid antigens [70]. This approach
llows exposure to all proteins in the adenovirus pro-
ein coat, leading to the presentation of multiple un-
eﬁned antigen epitopes [71]. To generate these ade-
ovirus-speciﬁc T-cell lines, DCs were infected with
ither wild-type Ad5 or Ad5 strain dl312, an Ad5
utant with the E1A and E3 regions deleted and
onsequently defective in early and late viral gene
xpression. It is important to note that the results
howed that the adenovirus-speciﬁc CTLs generated [
50n this way had extensive cross-reactivity in that CTLs
enerated with an Ad5 virus also lysed target cells
nfected with Ad11, Ad4, and Ad18 [71]. Such cross-
eactivity is important because it indicates that the
doptive transfer of adenovirus-speciﬁc CTLs gener-
ted in vitro against 1 adenovirus serotype may protect
mmunocompromised patients from infections by ad-
noviruses of many, if not all, serotypes.
Regn et al. [37] conﬁrmed the feasibility of the
reviously described approach and performed addi-
ional studies to simultaneously expand bispeciﬁc
TL populations by using LCLs that had been cocul-
ured on a CD40 ligand–expressing monolayer and
nfected with the Ad5 virus to prime autologous
BMCs. Using this methodology, they demonstrated
hat the resultant CTLs had speciﬁcity against both
BV and adenovirus and that this was mediated by
oth CD4 and CD8 T cells. Hamel et al. [72] have
lso generated bispeciﬁc CTLs for adenovirus and
BV and also for adenovirus and CMV [72]. They
sed DCs transduced with recombinant adenovirus
ncoding CMV pp65 or EBV EBNA 3C and used
hese cells to stimulate PBMCs. The resulting CTLs
ere able to kill target cells infected with laboratory
trains of these viruses.
To date there have been no clinical trials using
denovirus-speciﬁc CTLs. However, as a proof of
rinciple for the use of T-cell therapy for adenoviral
nfection, 1 group reported a case of a 19-year-old
an who underwent a T cell–depleted 6/6 matched
elated donor BMT for T-cell lymphoblastic lym-
homa [3]. His posttransplantation course was un-
omplicated until day 42, when he presented with
igniﬁcant hemorrhagic cystitis secondary to adenovi-
us infection. The patient did not respond to foscarnet
nd was given donor leukocytes (106 CD3 cells per
ilogram) on day 61. After 5 weeks, the patient’s
ematuria cleared, and urine adenovirus cultures were
egative by day 94. This successful treatment of
igniﬁcant adenovirus infection with donor leukocyte
nfusion therefore supports the rationale for the adop-
ive transfer of adenovirus-speciﬁc CTLs.
To assess the safety of donor-derived adenovirus-
peciﬁc CTLs as prophylaxis and treatment after
CT, our group has developed a protocol that has
een approved by our institutional review board and
he Recombinant DNA Advisory Committee for the
se of adenovirus-speciﬁc CTLs as prophylaxis or
reatment of adenoviral infection after SCT. In this
rotocol, we aim to generate and expand adenovirus-
peciﬁc CTLs by stimulating donor PBMCs with
onocytes and LCLs transduced with an Ad5f35 vec-
or. We have demonstrated that adenovirus-speciﬁc
olyclonal T-cell lines with both cytotoxic and helper
unction can simply and reproducibly be expanded
rom healthy donors in vitro by using this method
73]. Further, these CTLs recognize and kill autolo-
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Adoptive Immunotherapy for Posttransplantation Viral Infections
Bous cells infected with wild-type adenovirus isolates
rom multiple different serotypes and groups, imply-
ng that the virion proteins are responsible for gener-
ting at least some of our in vivo T-cell memory
esponse to adenovirus and that T-cell epitopes that
re recognized are conserved between different sero-
ypes [73]. Thus, adenovirus immunotherapy is a prac-
ical objective that will determine whether virion pro-
eins provide protective CTL epitopes.
ESPIRATORY VIRUSES
The respiratory viruses, particularly RSV, inﬂu-
nza, parainﬂuenza, and picornaviruses, are increas-
ngly recognized as signiﬁcant pathogens in posttrans-
lantation populations. In a prospective surveillance
tudy of 156 patients infected with RSV, inﬂuenza, or
arainﬂuenza, 64% developed pneumonia and 30%
ied [74]. In a large prospective European Bone Mar-
ow Transplantation Group study, over the course of
0 months, 40 patients developed respiratory viral
nfections, and the overall mortality rate was approx-
mately 25% [75]. These studies further demonstrate
he signiﬁcant effect of human respiratory viruses in
ransplant-associated morbidity and mortality and
articularly highlight the importance of focusing on
trategies to prevent and treat such infections.
One limitation of immunotherapy strategies for
espiratory viruses is that, with the exception of inﬂu-
nza, knowledge of viral immunology is less complete
han for CMV and EBV. Although there are some
eports identifying epitopes for viruses such as RSV
76], there are no in vitro studies showing that it is
ossible to generate CTLs from BMT donors that
ecognize recipient infected cells. A second limitation
s logistic in that these viruses cause the greatest mor-
idity in the early posttransplantation period, and it
ay not be feasible to generate CTLs in time to cover
his period of high risk. There is one report suggesting
hat donor leukocytes may have activity in RSV: donor
ymphocytes were administered to a patient with
lasma cell leukemia who relapsed 1 year after trans-
lantation and developed RSV-associated interstitial
neumonia [77]. One week after donor lymphocyte
nfusion (DLI) his respiratory status improved, with
mproved arterial oxygen pressures and a decrease in
he pulmonary inﬁltrates detected on computed to-
ography. A repeat nasal swab was negative for RSV.
owever, his plasma cell leukemia rapidly progressed,
nd he died of septic shock approximately 3 weeks
fter DLI. RSV was not detected in the bronchoal-
eolar lavage ﬂuid obtained after death [77]. This
tudy therefore suggests a role for T-cell therapy in
he management of RSV. It is of note that no inﬂam-
atory response was observed after DLI, as has been
een with EBV-speciﬁc CTL in the context of EBV- s
B&MTssociated pulmonary disease [32]. The risk of a dev-
stating inﬂammatory response with T-cell therapy is,
owever, a real possibility, and caution is warranted
hen immunotherapeutic approaches for respiratory
iseases are considered.
LTERNATIVE STRATEGIES TO AUGMENT ANTIVIRAL
MMUNITY
The strategies outlined previously to generate vi-
us-speciﬁc CTLs target only 1 or 2 viruses. The use
f a broader range of donor T cells may provide more
ide-ranging protection but carries the risk of allo-
eactivity. Two approaches are under evaluation to
inimize alloreactivity.
onor T Cells Transduced with Suicide Genes
One solution to the problem of alloreactivity when
onor leukocyte infusions are administered is to trans-
uce the T cells with a suicide gene. The suicide gene
sed most frequently is the herpes simplex virus
–thymidine kinase gene, which renders transduced
ells sensitive to ganciclovir so that they can be sub-
equently ablated should signs of GVHD develop.
everal studies suggest that the use of such cells early
r late after transplantation is associated with no acute
oxicity; persistent circulation of the gene-modiﬁed
ells and alloreactive T cells seem to be sensitive to
anciclovir [78,79]. However, 2 concerns with this
pproach are that the transgene may be immunogenic
80] and that the ex vivo activation necessary for ret-
oviral transduction may inhibit virus-reactive cells
81]. An alternative suicide gene that solves the im-
unogenicity problem is a chimeric human protein
hat expresses the Fas intracellular domain, with 2
opies of an FK506-binding protein. In vitro, trans-
uced primary human T lymphocytes retrovirally
ransduced to express the Fas/FK506 chimeric protein
unctioned the same as untransduced cells. However,
ransduced cells rapidly underwent apoptosis with the
ddition of subnanomolar concentrations of AP1903,
bivalent dimerizer drug that binds FK506 binding
rotein and induces Fas cross-linking. T cells were
liminated regardless of their proliferation state, and
his AP1903/Fas system contains only human compo-
ents, suggesting that it may be a promising alterna-
ive to herpes simplex virus 1–thymidine kinase for the
emoval of alloreactive T cells and the prevention/
reatment of graft-versus-host disease [82]. Recent
tudies suggest that the problem of activation-induced
ell death depleting tumor and virus-reactive cells
rom the ﬁnal product can be overcome by using both
D3 and CD28 for T-cell activation [83].
llodepleted T Cells
An alternative strategy to reconstitute antigen-
peciﬁc responses to multiple viruses, as well as tumor
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1ells, would be to selectively deplete the graft of allo-
eactive cells that initiate graft-versus-host disease
hile preserving tumor- and virus-speciﬁc cells. Allo-
eactive cells express activation markers after exposure
o alloantigens, including CD69, CD147, and the in-
erleukin-2 receptor CD25, which is expressed within
he ﬁrst 24 hours of T-cell activation. In a study using
CD25 immunotoxin to deplete alloreactive T cells
x vivo, the residual T cells were able to respond in a
hird-party mixed lymphocyte reaction or to viral or
yeloid leukemia–associated antigens [84]. In similar
tudies using CD69 and CD25 antibodies to deplete
ctivated cells after culture of donor cells with recip-
ent cells, the residual T-cell population retained
elper and CTL responses against foreign antigens
ut was speciﬁcally devoid of responses to recipient
LA antigens [85-87]. Several groups are now initi-
ting clinical trials with this strategy, and 1 study has
een published [88]. Fifteen patients received 1 to 8
05 allodepleted T cells per kilogram between days 15
nd 47 after transplantation. No patient developed
reater than grade II graft-versus-host disease, and
vidence for early T-cell expansion was shown in 3
atients with continuing viral infections [88]. In com-
arison with similar patients who received CD34-
elected haploidentical transplants alone, recipients of
llodepleted cells seemed to have more rapid recovery
f T-cell numbers and response to mitogen [88].
rafting of Chimeric Receptors
The generation of virus-speciﬁc T cells ex vivo is
imited by the requirement for expression of an ap-
ropriate antigen by an effective APC and for a sero-
ositive donor. One means of circumventing this
roblem is retroviral transduction of genes encoding a
CR from a T cell speciﬁc to a particular antigen
resented on MHC, which should confer that speci-
city to the transduced cell, thereby bypassing the
ecessity to isolate and expand virus-speciﬁc CTLs
rom every donor. For example, transduction of a
CR speciﬁc for an LMP2 peptide was able to trans-
er CTL activity from a LMP2 peptide–speciﬁc CTL
lone to a stimulated PBMC population [89]. An al-
ernate approach is to transduce T cells with chimeric
eceptors that are composed of an extracellular do-
ain usually derived from immunoglobulin variable
hains, which recognizes and binds target antigens
ttached to a segment of the TCR- chain, which
ransmits an activation signal to the T cell. In trials in
olid tumors, T cells expressing transgenic antigen-
peciﬁc receptors have had limited clinical success, in
art because engagement of the chimeric receptor
lone is insufﬁcient to sustain T-cell growth and ac-
ivation. One means of solving this problem is to
ransduce antigen-speciﬁc T cells rather than nonspe-
iﬁcally activated cells and take advantage of the co-
52timulation provided to the native TCR by antigen;
his approach has shown promise in preclinical studies
ith EBV-speciﬁc [90] or alloreactive T cells [91].
ONCLUSIONS AND FUTURE DIRECTIONS
The association of viral infection with deﬁcient
iral immunity and the efﬁcacy of donor leukocyte
nfusions for the treatment of various viral infections
nd virus-speciﬁc CTLs for the treatment of CMV
nd EBV demonstrates the potential of virus-speciﬁc
mmunotherapy. Current challenges are to deﬁne the
mmune response for some of the major pathogens,
uch as adenovirus, and to devise strategies to provide
road antiviral protection by either generating multi-
irus-speciﬁc CTLs or a T-cell product with a broad
ntiviral component but a low risk of alloreactivity.
inally, the availability of quantitative and functional
ssays of virus-speciﬁc immunity is critical for the
etection and preemptive treatment of at-risk pa-
ients.
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